Open AccessMulti-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer
Author(s) -
Paige Blinn,
Ravi Shridhar,
Taylor Maramara,
Jamie Huston,
Kenneth Meredith
Publication year - 2020
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo.2019.12.03
Subject(s) - medicine , pancreatic cancer , neoadjuvant therapy , chemotherapy , oncology , folfirinox , hazard ratio , proportional hazards model , cancer , surgery , gastroenterology , breast cancer , oxaliplatin , confidence interval , colorectal cancer
We sought to examine the impact of neoadjuvant chemotherapy (NCT), single agent (SA) or multi-agent (MA) chemotherapy, and chemoradiation (NCRT) on response and survival in pancreatic cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom